Acadian Asset Management’s Impax Laboratories, Inc. IPXL Stock Holding History

Acadian Asset Management’s Portfolio IPXL Stock Details IPXL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-166	Closed	-$2K	–	1716
2017 Q1	$2K	Sell	166 -22,464	-99%	-$271K	﹤0.01%	1523
2016 Q4	$299K	Sell	22,630 -242,153	-91%	-$4.14M	﹤0.01%	950
2016 Q3	$6.28M	Buy	264,783 +141,224	+114%	+$3.8M	0.03%	336
2016 Q2	$3.56M	Buy	123,559 +123,459	+123,459%	+$4.02M	0.02%	437
2016 Q1	$3K	Buy	+100	New	+$3.52K	﹤0.01%	1313
2014 Q4	–	Sell	-67,790	Closed	-$1.61M	–	1366
2014 Q3	$1.61M	Sell	67,790 -324,117	-83%	-$8.3M	0.01%	514
2014 Q2	$11.8M	Buy	391,907 +360,341	+1,142%	+$9.72M	0.06%	267
2014 Q1	$834K	Sell	31,566 -103,627	-77%	-$2.59M	﹤0.01%	594
2013 Q4	$3.4M	Buy	135,193 +130,009	+2,508%	+$2.9M	0.02%	395
2013 Q3	$106K	Buy	+5,184	New	+$107K	﹤0.01%	808

Other funds holding IPXL

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Acadian Asset Management's IPXL Position: Q2 2017 in Review

Acadian Asset Management sold out of Impax Laboratories, Inc. (IPXL) in Q2 2017, closing a stake of 166 shares — an estimated $2K sold.

Acadian Asset Management first reported a position in IPXL in Q3 2013 and held it in 10 quarters. The position peaked at $11.8M in Q2 2014. 172 funds tracked by Wall St. Rank hold IPXL as of Q2 2017.

Acadian Asset Management reported no remaining Impax Laboratories, Inc. position as of Q2 2017 after selling out during the quarter.
Acadian Asset Management sold 166 Impax Laboratories, Inc. shares in Q2 2017, an estimated $2K.
Acadian Asset Management first reported a position in Impax Laboratories, Inc. in Q3 2013 and held it in 10 quarters.
Acadian Asset Management's Impax Laboratories, Inc. position peaked at $11.8M in Q2 2014.
172 funds tracked by Wall St. Rank held Impax Laboratories, Inc. as of Q2 2017.

Based on Acadian Asset Management's 13F filing for Q2 2017, filed 25 Jul 2017.